Background: Our aim was to set the FISH combination of del(17p13), t(4;14), 1q21 gain and del(1p32), four adverse cytogenetic factors rarely evaluated together, and compare our technical thresholds with those defined in the literature.
Methods: Two hundred thirty-three patients with MM at diagnosis were studied using FISH to target 4 unfavorable cytogenetic abnormalities: 17p13 deletion, t(4;14) translocation, 1p32 deletion and 1q21 gain. Technical thresholds were determined for each probe using isolated CD138-expressing PC from patients without MM.
Patients with acute myeloblastic leukemia or higher risk myelodysplastic syndromes with 5q deletion (generally within a complex karyotype) respond poorly to intensive chemotherapy and have very poor survival. In this population, we evaluated escalating doses of lenalidomide combined with intensive chemotherapy in a phase II study. Treatment consisted of daunorubicin (45 mg/m/day, days 1-3 in cohort 1, escalated to 60 mg/m/day, days 1-3 in cohorts 2 and 3) combined with cytosine arabinoside (200 mg/m/day, days 1-7) and lenalidomide (10 mg/day, days 1-21 in cohorts 1 and 2, escalated to 25 mg/day, days 1-21 in cohort 3).
View Article and Find Full Text PDFIntroduction: The aim of this study was to assess diabetic retinopathy progression during pregnancy and to determine the predictive factors of this progression.
Patients And Methods: Monocentric retrospective study including 77 consecutive diabetic women submitted to a multidisciplinary medical follow-up during pregnancy with at least one ophthalmologic examination per trimester with ocular fundus photographs.
Results: Diabetic retinopathy was evidenced in 21 (27.